Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.
Rey-Búa B, Grande C, Sánchez Blanco JJ, Abrisqueta P, Gutiérrez A, Ramírez Páyer Á, Giné E, Zeberio Etxetxipia I, Terol MJ, de la Cruz Vicente F, Andreu R, Ramirez MJ, de la Fuente A, Viguria MC, Peñarrubia MJ, Jiménez-Ubieto A, Montes-Moreno S, López-Guillermo A, Caballero MD, Martín García-Sancho A. Rey-Búa B, et al. Among authors: de la cruz vicente f. Clin Cancer Res. 2024 Sep 3;30(17):3704-3714. doi: 10.1158/1078-0432.CCR-24-0183. Clin Cancer Res. 2024. PMID: 38900037 Clinical Trial.
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, García-Domínguez DJ, Hontecillas-Prieto L, Espejo-García P, Fernández-Román I, Provencio-Pulla M, Sánchez-Beato M, Navarro M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Sánchez-Margalet V, Rueda-Domínguez A, de la Cruz-Merino L. Palazón-Carrión N, et al. Among authors: de la cruz vicente f. Clin Cancer Res. 2022 Sep 1;28(17):3658-3668. doi: 10.1158/1078-0432.CCR-22-0588. Clin Cancer Res. 2022. PMID: 35727601 Free PMC article. Clinical Trial.
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
Jiménez-Cortegana C, Palazón-Carrión N, Martin Garcia-Sancho A, Nogales-Fernandez E, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Rueda Dominguez A, Casanova-Espinosa M, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Labrador J, Salar-Silvestre A, Rodriguez-Abreu D, Galvez-Carvajal L, Provencio M, Sánchez-Beato M, Guirado-Risueño M, Espejo-García P, Lejeune M, Álvaro T, Sánchez-Margalet V, de la Cruz-Merino L; Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA). Jiménez-Cortegana C, et al. Among authors: de la cruz vicente f. J Immunother Cancer. 2021 Jun;9(6):e002323. doi: 10.1136/jitc-2020-002323. J Immunother Cancer. 2021. PMID: 34158317 Free PMC article.
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Hontecillas-Prieto L, García-Domínguez DJ, Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Sánchez-León ML, Silva-Romeiro S, Flores-Campos R, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, Provencio-Pulla M, Sánchez-Beato M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Rueda-Domínguez A, Sánchez-Margalet V, de la Cruz-Merino L. Hontecillas-Prieto L, et al. Among authors: de la cruz vicente f. Front Immunol. 2024 Feb 26;15:1293931. doi: 10.3389/fimmu.2024.1293931. eCollection 2024. Front Immunol. 2024. PMID: 38469299 Free PMC article. Clinical Trial.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators. Morschhauser F, et al. N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104. N Engl J Med. 2018. PMID: 30184451 Free PMC article. Clinical Trial.
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
Cabrero M, López-Corral L, Jarque I, de la Cruz-Vicente F, Pérez-López E, Valcárcel D, Sanz J, Espigado I, Ortí G, Martín-Calvo C, de la Serna J, Caballero D; Grupo Español de Trasplante Hematopoyético (GETH) and Grupo Español de Linfomas y Trasplante Autólogo (GELTAMO). Cabrero M, et al. Among authors: de la cruz vicente f. Bone Marrow Transplant. 2024 Mar;59(3):359-365. doi: 10.1038/s41409-023-02171-5. Epub 2024 Jan 2. Bone Marrow Transplant. 2024. PMID: 38167647 Clinical Trial.
Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry.
Muniesa C, Gallardo F, García-Doval I, Estrach MT, Combalia A, Morillo-Andújar M, De la Cruz-Vicente F, Machan S, Moya-Martínez C, Rovira R, Sanchez-Gonzalez B, Acebo E, Amutio E, Peñate Y, Losada-Castillo MDC, García-Muret MP, Iznardo H, Román-Curto C, Cañueto J, Fernández-de-Misa R, Flórez Á, Izu RM, Torres-Navarro I, Zayas A, Pérez-Paredes G, Blanes M, Yanguas JI, Pérez-Ferriols A, Callejas-Charavia M, Ortiz-Romero PL, Pérez-Gil A, Prieto-Torres L, González-Barca E, Servitje O. Muniesa C, et al. Among authors: de la cruz vicente f. J Eur Acad Dermatol Venereol. 2023 Jan;37(1):57-64. doi: 10.1111/jdv.18563. Epub 2022 Sep 9. J Eur Acad Dermatol Venereol. 2023. PMID: 36017748
Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma.
Carrillo-Cruz E, Marín-Oyaga VA, de la Cruz Vicente F, Borrego-Dorado I, Ruiz Mercado M, Acevedo Báñez I, Solé Rodríguez M, Fernández López R, Pérez Vega H, Calderón-Cabrera C, Espigado Tocino I, Pérez-Simón JA, Vázquez-Albertino R. Carrillo-Cruz E, et al. Among authors: de la cruz vicente f. Hematol Oncol. 2015 Dec;33(4):151-8. doi: 10.1002/hon.2181. Epub 2014 Nov 19. Hematol Oncol. 2015. PMID: 25407794
Improvement over the years of long-term survival in high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy.
Calderón-Cabrera C, Márquez-Malaver FJ, de la Cruz-Vicente F, Falantes F, Carrillo E, Parody R, Montero I, González Campos J, Martino ML, Carmona M, Pérez-Simón JA, Espigado I. Calderón-Cabrera C, et al. Among authors: de la cruz vicente f. Transplant Proc. 2013;45(10):3665-7. doi: 10.1016/j.transproceed.2013.11.007. Transplant Proc. 2013. PMID: 24314990
26 results